ScienceVest Weekly Deal

Get a closing, diligenced private science deal to your inbox

get it
Reviews
Discussion
MakersThere are no makers yet
You need to become a Contributor to join the discussion.
J. Ramphis Castro
J. Ramphis Castro@jramphis · Investor @ ScienceVest
Hi Everyone! One of the co-founders for ScienceVest here. I'll be around all day to answer questions.
Joaquín Beltrán
Joaquín Beltrán@joaquin_beltran · Creator @ Speak Up America
This sounds awesome! Is this specifically for startups or would university scientist be able to work with you as well? If so, how would that relationship work?
J. Ramphis Castro
J. Ramphis Castro@jramphis · Investor @ ScienceVest
@joaquin_beltran We typically help scientists connect with the right resources that are stage-appropriate and track their progress over time to a point where we can be helpful, typically when they are ready to raise outside funding.
UpKeep Maintenance Management
UpKeep Maintenance Management@onupkeep · Founder of UpKeep Maintenance Management
Cool stuff man!
Miguel Rios
Miguel Rios@miguelrios · Engineering Manager at Twitter
This looks amazing! Congrats! Quick question: startups in hard sciences usually take a long time to produce an exit (IPO/acquisition, etc.). How do you measure deal quality or what "success" looks like for a particular deal in an early-stage startup?
J. Ramphis Castro
J. Ramphis Castro@jramphis · Investor @ ScienceVest
@miguelrios fantastic question and something worth it's own blog post, but the short version is there are a few trends that only recently have come together to make these types of companies even more attractive for the right kind of investor than they've been historically (think Intel, Google, Genentech, Tesla, etc). These are many of the trends that apply to all startups (costs of storage, computing, etc nearing $0), but new ones that also apply to science (costs for megabase of DNA sequence, per genome, etc also approaching $0) on top of new startups that provide services that typically were reserved for big Co's (ScienceExchange being the UpWork for science talent, Genscript as the mechanical turk for research, etc). These make the path for these companies to IPO/Exit is now similar to your average tech startup (~11yr avg time to IPO), but with much better economics for a shorter hold period. One of the most recent companies that best highlight these trends recently is Stemcentrx (acquired by AbbVie for $10.2B, ~7 yrs to exit).
Pame Valdés
Pame Valdés@pamevls · CEO, Beek
I love this!